Ең жақсы сүйек рагының дәрігерлері - ЖОҒ-73 дәрігерлер

Контент Bookimed редакциялық саясатына сәйкес келеді және оның сапасын тексерген

Фахад Мавлюд

Konstantinos Ferentinos

  • Жаңа
  • 12 жылдар тәжірибе
  • Кипр, Кипр Республикасы, German Medical Institute (GMI)
    • Education: 
    •  
    • 2001-2007: University of Ioannina Medical School, Greece.
    • 2007: Degree in Medicine.
    • 2013: Doctoral degree from the Medical School of the Johann Wolfgang Goethe University, Frankfurt (Dr. Med)
    • 09.2016 – Today: Master’s in Healthcare Business Studies.

    Professional experience:

    04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach

    05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach

    • 01.2016 – 06.2017: Senior physician in the Department of interventional Radiation Oncology, Medical Center Athens
    •  
    • 07.2017 – Today: Head of the Department of Radiation Oncology at the German Oncology Center, Limassol, Cyprus.
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Abdullah Sakin

  • 4.5 Жақсы 2 пікірлер
  • 18 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • Толығырақ оқу
Сүйек деформациясын түзету операциясы
6 000 $ - 10 000 $
Сүйекті резекциялау
8 000 $ - 12 000 $
Тік ішек қатерлі ісігінде сәулелік терапия
4 000 $ - 6 000 $
Ақпарат

Manchenko Dina

  • Жаңа
  • 12 жылдар тәжірибе
  • Украина, Ужғород, Expert клиникасы
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Evrim Metcalfe

  • 4.5 Жақсы 2 пікірлер
  • 27 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital
  • Experience

    2021 year - 2022 year

    Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

    2021 year - 2022 year

    Department of Radiation Oncology, Biruni University Faculty of Medicine

    2020 year - 2021 year

    Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

    2017 year - 2020 year

    Clinical Manager of Radiation Oncology, Neolife Medical Center

    2016 year - 2017 year

    Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

    2011 year - 2016 year

    Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

    2010 year - 2011 year

    Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

    2008 year - 2010 year

    Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

    2006 year

    Medical Faculty, Dokuz Eylül University

    2006 year - 2008 year

    Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

    2000 year - 2006 year

    Medical Faculty, Dokuz Eylül University

     

    Education

    2022 year

    Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

    2022 year

    Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

    2021 year

    Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

    2017 year

    Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

    2017 year

    Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

    2006 year

    Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

    2006 year

    Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

    1998 year

    Ege University, Faculty of Medicine

     

     

  • Толығырақ оқу
Сүйек деформациясын түзету операциясы
6 000 $ - 10 000 $
Сүйекті резекциялау
8 000 $ - 12 000 $
Тік ішек қатерлі ісігінде сәулелік терапия
4 000 $ - 6 000 $
Ақпарат

Jaume Mora Graupera

  • 4.8 Керемет 41 пікірлер
  • 29 жылдар тәжірибе
  • аккредитациялар:
  • Испания, Барселона, SJD Barcelona Children’s Hospital
  • Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Sezer Saglam

  • 5 Керемет 45 пікірлер
  • 28 жылдар тәжірибе
  • аккредитациялар:
  • Түркия, Істанбұл, Istanbul Florence Nightingale Hospital
  • Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

    Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Dror Levin

  • 4.5 Жақсы 151 пікірлер
  • 40 жылдар тәжірибе
  • Израиль, Тель-Авів, Sourasky Medical Center (Ichilov)
  • Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Mustafa Ondzhel

  • 4.6 Керемет 471 пікірлер
  • 23 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Mega University Hospital
  • Professor of oncosurgery and proctology

Ақпарат

Sternheim Amir

  • 4.5 Жақсы 151 пікірлер
  • 27 жылдар тәжірибе
  • Израиль, Тель-Авів, Sourasky Medical Center (Ichilov)
  • Dr. Sternheim Amir is an experienced orthopaedic surgeon. He specializes in orthopaedic oncology, joint replacement, and complex hip and knee reconstruction. He is known for using advanced 3D technology and computer-assisted methods. These tools help him plan surgeries with high precision, especially for predicting femur fractures in patients with metastatic disease.

    Dr. Amir has published many research papers and has spoken at major medical conferences. His main interests are sarcoma and metastatic bone cancer. He has received several awards, such as the Outstanding Resident Award at Tel-Aviv Medical Center. He has also earned grants from the Israeli Cancer Society and the University of Toronto. Dr. Amir is an active member of MSTS, CTOS, and ISOLS, which shows his strong reputation in the field.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Tahsin Ozadli

  • 4.9 Керемет 53 пікірлер
  • 22 жылдар тәжірибе
  • Түркия, Істанбұл, Valued Med Hub Hospitals
  • Education and Expertise

    Selcuk University Meram Faculty of Medicine - Medical Education

    Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

     

    Experience

    Malatya State Hospital Internal Diseases Clinic

    Ankara Oncology Hospital Medical Oncology Clinic

    Erzurum Regional Training and Research Hospital Medical Oncology Clinic


    AREAS OF INTEREST

    Lung cancer

    esophageal cancer

    Gastric cancer

    breast cancer

    Gastrointestinal surgery

    https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Jakov Bikels

  • 4.5 Жақсы 151 пікірлер
  • 32 жылдар тәжірибе
  • Израиль, Тель-Авів, Sourasky Medical Center (Ichilov)
  • Orthopedic Oncologist. Head of the Department for the Treatment of Metastatic Bone Disease. TOP World Doctor of Treatment of Chondrosarcoma
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Wolfgang Köstler

  • 4.7 Керемет 152 пікірлер
  • 21 жылдар тәжірибе
  • Австрия, Вена, Wiener Privatklinik
  • Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Sebastian Keil

  • 4.7 Керемет 60 пікірлер
  • 21 жылдар тәжірибе
  • Германия, Золинген, Medical Center in Solingen
  • Professor Dr. Sebastian Keil is a recognized expert in the field of interventional radiology and is considered one of the leading specialists in Germany and in Europe. He is a professional in his field, thanks to whom many patients receive timely diagnosis and effective treatment. Professor Keil and his team of specialists have extensive knowledge of anatomy, physiology and pathology, as well as an understanding of the various methods of performing and interpreting radiological examinations.
  • Толығырақ оқу
Ақпарат

Tahsin Ozatli

  • 4.4 Жақсы 16 пікірлер
  • 2015 жылдар тәжірибе
  • Түркия, Істанбұл, Istinye University Liv Hospital Bahcesehir
  • Oncologist
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ercan Ozden

  • 5 Керемет 1 пікірлер
  • 26 жылдар тәжірибе
  • Түркия, Істанбұл, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Yusuf Acikgoz

  • 4.8 Керемет 5 пікірлер
  • 9 жылдар тәжірибе
  • Түркия, Анқара, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Nail Paksoy

  • 4.5 Жақсы 2 пікірлер
  • 14 жылдар тәжірибе
  • аккредитациялар:
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Толығырақ оқу
Сүйек деформациясын түзету операциясы
6 000 $ - 10 000 $
Сүйекті резекциялау
8 000 $ - 12 000 $
Тік ішек қатерлі ісігінде сәулелік терапия
4 000 $ - 6 000 $
Ақпарат

Dr Murat Ayhan

  • 5 Керемет 7 пікірлер
  • 35 жылдар тәжірибе
  • Түркия, Істанбұл, Liv Hospital Vadistanbul
  • Areas of Interests

    • Breast cancer
    • Lung cancer
    • Colorectal cancers
    • Gynecological and urogenital cancers
    • Molecular Oncology

    Education:

    • Kızıltepe Anatolian High School 2001
    • Dicle University Faculty of Medicine 2007
    • Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
    • Kartal City Hospital 2021
    • Associate Professor of Medical Oncology 2023

    Experience:

    • Liv Hospital Ulus
    • Adıyaman University Training and Research Hospital
    • Istanbul Umraniye Training and Research Hospital
    • Istanbul Umraniye Training and Research Hospital

    Research:

    • Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
    • Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
    • Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
    • Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
    • Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
    • Publications:
    • Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
    • Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
    • Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
    • Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
    • Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
    • Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
    • Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
    • Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
    • Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
    • Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
    • Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
    • Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
    • Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
    • Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
    • Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
    • Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
    • Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
    • Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
    • Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
    • Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
    • Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
    • Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
    • Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
    • Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
    • Book Writing:
    • Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
    • Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
    • Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
    • Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

     

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Osman Kostek

  • 5 Керемет 3 пікірлер
  • 21 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Acibadem District Hospital
  • Education

    • (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
    • (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

    Career

    • (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
    • (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
    • (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
    • (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Onder Ofluoglu

  • 4.4 Жақсы 30 пікірлер
  • аккредитациялар:
  • Түркия, Істанбұл, Medical Park Göztepe Hospital Complex
  • Dr. Önder Ofluoğlu is an experienced orthopedic surgeon with 30 years of experience. He specializes in orthopedic surgery, orthopedic oncologic surgery, hand microsurgery, bone and soft tissues tumors, and trauma surgery. He is an author of over 50 documents and has over 200 citations. He is a member of the Connective Tissue Oncology Society, European Federation of National Associations of Orthopaedics and Traumatology, Turkish Association of Orthopaedics Oncology, Turkish Association of Orthopaedics and Traumatology, and Association for the Study and Application of Methods of Ilizarov. He currently works in Medical Park Göztepe Hospital.

  • Толығырақ оқу
Сүйекті резекциялап, имплантпен ауыстыру
15 000 $ - 70 000 $
Ақпарат

Дәрігер мен клиниканы дұрыс қалай таңдау керек: сарапшылардың ұсыныстары

Дәрігер немесе клиника таңдағанда осы негізгі сәттерді есте сақтаңыз:
Біліктілікті тексеріңіз
ISAPS, JCI және т.б. сияқты ұйымдардан сертификаттардың болуына көз жеткізіңіз.
Процедуралардың табыстылығы туралы біліңіз
Сізге қажет саладағы үлкен тәжірибесі бар дәрігерлерді таңдаңыз.
Науқастардың пікірлерін оқыңыз
Олардың тәжірибесі туралы тікелей білу үшін Bookimed сайтындағы нақты науқастардың пікірлерімен танысыңыз.
Тиімді коммуникация мүмкіндігіне көз жеткізіңіз
Сіздің барушы максималды жайлы өтуі үшін аудармашы қызметтерін ұсынатын клиникаларды таңдаңыз.
Қолжетімді қызметтер туралы сұраңыз
Клиника тұрғын үй және трансфер ұсына ма, сондай-ақ бағаларды біліңіз.
Шетелде клиника таңдау қиын болуы мүмкін. Bookimed командасы 800 мыңнан астам науқасқа көмектесті және Сіздің алаңдаушылықтарыңызды түсінеді. Біз сенімді дәрігерлерді, баға мен сапаның ең жақсы арақатынасы бар нұсқаларды және тіпті күрделі жағдайлар үшін шешімдерді қалай табуды білеміз. Біз осы жолдың әрбір қадамында Сізді қолдауға дайынбыз.
Ян Мациевский
Дәрігер-координаторлар тобының басшысы